Literature DB >> 17583556

Mirk/Dyrk1B in cancer.

Eileen Friedman1.   

Abstract

Mirk/Dyrk1B is a member of a conserved family of serine/threonine kinases which are activated by intramolecular tyrosine phosphorylation, and which mediate differentiation in different tissues-Mirk in skeletal muscle, Dyrk1A in the brain, etc. One role of Mirk in skeletal muscle differentiation is to block cycling myoblasts in the G0 quiescent state by modification of cell cycle regulators, while another role of Mirk is to limit apoptosis in fusing myoblasts. Amplification of the Mirk gene, upregulation of Mirk expression and/or constitutive activation of this kinase have been observed in several different types of cancer. If coupled with a stress condition such as serum starvation which induces a quiescent state, depletion of Mirk by RNA interference using either synthetic duplex RNAi's or pSilencer-encoded RNAi's have decreased colony formation of different cancer cell lines and enhanced apoptosis induced by chemotherapeutic drugs. Mirk is activated by phosphorylation by the stress-activated SAPK kinases MKK3 and MKK6. Our working hypothesis is that Mirk is activated by this pathway in response to various stresses, and then acts as a checkpoint kinase to arrest damaged tumor cells in a quiescent state and allow cellular repair. Pharmacological inhibition of Mirk may enhance the anti-tumor effect of chemotherapeutic drugs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17583556     DOI: 10.1002/jcb.21451

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  36 in total

1.  Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells.

Authors:  Jingchun Gao; Zhong Zheng; Bhupendra Rawal; Michael J Schell; Gerold Bepler; Eric B Haura
Journal:  Cancer Biol Ther       Date:  2009-09-20       Impact factor: 4.742

2.  Regulation of MBK-2/DYRK by CDK-1 and the pseudophosphatases EGG-4 and EGG-5 during the oocyte-to-embryo transition.

Authors:  Ken Chih-Chien Cheng; Richard Klancer; Andrew Singson; Geraldine Seydoux
Journal:  Cell       Date:  2009-10-30       Impact factor: 41.582

Review 3.  New targets to treat obesity and the metabolic syndrome.

Authors:  Kathleen A Martin; Mitra V Mani; Arya Mani
Journal:  Eur J Pharmacol       Date:  2015-05-19       Impact factor: 4.432

4.  Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk).

Authors:  Andrew S Rosenthal; Cordelle Tanega; Min Shen; Bryan T Mott; James M Bougie; Dac-Trung Nguyen; Tom Misteli; Douglas S Auld; David J Maloney; Craig J Thomas
Journal:  Bioorg Med Chem Lett       Date:  2011-03-04       Impact factor: 2.823

5.  Cold-inducible RNA-binding protein (Cirp) interacts with Dyrk1b/Mirk and promotes proliferation of immature male germ cells in mice.

Authors:  Tomoko Masuda; Katsuhiko Itoh; Hiroaki Higashitsuji; Hisako Higashitsuji; Noa Nakazawa; Toshiharu Sakurai; Yu Liu; Hiromu Tokuchi; Takanori Fujita; Yan Zhao; Hiroyuki Nishiyama; Takashi Tanaka; Manabu Fukumoto; Masahito Ikawa; Masaru Okabe; Jun Fujita
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-18       Impact factor: 11.205

6.  G0 function of BCL2 and BCL-xL requires BAX, BAK, and p27 phosphorylation by Mirk, revealing a novel role of BAX and BAK in quiescence regulation.

Authors:  Yelena Janumyan; Qinghua Cui; Ling Yan; Courtney G Sansam; Mayda Valentin; Elizabeth Yang
Journal:  J Biol Chem       Date:  2008-09-25       Impact factor: 5.157

7.  Adenovirus type 5 E1A and E6 proteins of low-risk cutaneous beta-human papillomaviruses suppress cell transformation through interaction with FOXK1/K2 transcription factors.

Authors:  Jessica Komorek; Mohan Kuppuswamy; T Subramanian; S Vijayalingam; Elena Lomonosova; Ling-Jun Zhao; Joe S Mymryk; Kimberly Schmitt; G Chinnadurai
Journal:  J Virol       Date:  2010-01-06       Impact factor: 5.103

8.  Development of a sensitive non-radioactive protein kinase assay and its application for detecting DYRK activity in Xenopus laevis oocytes.

Authors:  Eva Lilienthal; Katharina Kolanowski; Walter Becker
Journal:  BMC Biochem       Date:  2010-05-20       Impact factor: 4.059

9.  The kinase Mirk is a potential therapeutic target in osteosarcoma.

Authors:  Cao Yang; Diana Ji; Edward J Weinstein; Edwin Choy; Francis J Hornicek; Kirkham B Wood; Xianzhe Liu; Henry Mankin; Zhenfeng Duan
Journal:  Carcinogenesis       Date:  2009-12-30       Impact factor: 4.944

10.  Ovarian cancer cells, not normal cells, are damaged by Mirk/Dyrk1B kinase inhibition.

Authors:  Jing Hu; Holly Deng; Eileen A Friedman
Journal:  Int J Cancer       Date:  2012-11-21       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.